Author

Mingkee Achom

Dana-Farber Cancer InstituteORCID 0000-0002-7908-3368Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1

Frequent Co-Authors

Ananthan SadagopaniD· 2 shared Jiao LiiD· 2 shared Prateek KhannaiD· 2 shared Srinivas Raghavan ViswanathaniD· 2 shared Toni K. ChoueiriiD· 2 shared Alessandro MeddaiD· 1 shared Bingchen LiiD· 1 shared Birgitta A. RybackiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Ananthan SadagopanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling

Simon Garinet, Karl Semaan, Jiao Li, Ananthan Sadagopan, John Canniff, Noa Phillips, Kelly S. Klega, Medha Panday, Hunter Savignano, Matthew P. Davidsohn, Kevin Lyons, Alessandro Medda, Prateek Khanna, Mingkee Achom, Prathyusha Konda, , Srinivas Raghavan Viswanathan

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

Journal of Clinical Investigation · Feb 1, 2026Peer-reviewedGenomics

TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma

Jiao Li, Kaimeng Huang, Meha Thakur, Fiona McBride, Ananthan Sadagopan, Daniel S Gallant, Prateek Khanna, Yasmin Nabil Laimon, Bingchen Li, Razan Assaad Mohanna, Maolin Ge, Cary N. Weiss, Mingkee Achom, Qingru Xu, Sayed Matar, , Srinivas Raghavan Viswanathan

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

Nature Metabolism · Feb 6, 2025Peer-reviewedCancer Biology